Year |
Citation |
Score |
2023 |
Kim D, Herdeis L, Rudolph D, Zhao Y, Böttcher J, Vides A, Ayala-Santos CI, Pourfarjam Y, Cuevas-Navarro A, Xue JY, Mantoulidis A, Bröker J, Wunberg T, Schaaf O, Popow J, ... ... Lito P, et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature. PMID 37258666 DOI: 10.1038/s41586-023-06123-3 |
0.366 |
|
2021 |
Zhao Y, Murciano-Goroff YR, Xue JY, Ang A, Lucas J, Mai TT, Da Cruz Paula AF, Saiki AY, Mohn D, Achanta P, Sisk AE, Arora KS, Roy RS, Kim D, Li C, ... ... Lito P, et al. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature. PMID 34759319 DOI: 10.1038/s41586-021-04065-2 |
0.349 |
|
2021 |
Zhao Y, Xue JY, Lito P. Suppressing Nucleotide Exchange to Inhibit KRAS-Mutant Tumors. Cancer Discovery. 11: 17-19. PMID 34003780 DOI: 10.1158/2159-8290.CD-20-1331 |
0.304 |
|
2020 |
Kim D, Xue JY, Lito P. Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients. Cell. PMID 33065029 DOI: 10.1016/j.cell.2020.09.044 |
0.302 |
|
2020 |
Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, ... ... Lito P, et al. KRAS Inhibition with Sotorasib in Advanced Solid Tumors. The New England Journal of Medicine. PMID 32955176 DOI: 10.1056/Nejmoa1917239 |
0.377 |
|
2020 |
Xue JY, Zhao Y, Aronowitz J, Mai TT, Vides A, Qeriqi B, Kim D, Li C, de Stanchina E, Mazutis L, Risso D, Lito P. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature. PMID 31915379 DOI: 10.1038/S41586-019-1884-X |
0.457 |
|
2020 |
Arbour KC, Rizvi H, Plodkowski AJ, Halpenny D, Hellmann MD, Heller G, Knezevic A, Yu HA, Ladanyi M, Kris MG, Arcila ME, Rudin CM, Lito P, Riely GJ. Clinical characteristics and anti-PD-(L)1 treatment outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer. Journal of Clinical Oncology. 38: 9596-9596. DOI: 10.1200/Jco.2020.38.15_Suppl.9596 |
0.365 |
|
2020 |
Murciano-Goroff YR, Lebow ES, Tu H, Li M, Lim LP, Arbour KC, Travis W, Solit DB, Ladanyi M, Jones DR, Rudin CM, Martinez A, Myers ML, Makhnin A, Razavi P, ... ... Lito P, et al. Abstract 12: Characterizing KRAS G12C and other mutations in plasma ctDNA from patients with lung cancer Clinical Cancer Research. 26: 12-12. DOI: 10.1158/1557-3265.Advprecmed20-12 |
0.36 |
|
2020 |
Murciano-Goroff YR, Arbour KC, Offin MD, Tu HY, Lebow ES, Shaffer TS, Bertucci C, Hosseini SA, Garg K, Lim LP, Li M, Chang JC, Reis-Filho JS, Razavi P, Isbell JM, ... ... Lito P, et al. Abstract 709: The utility of plasma ctDNA for detection ofKRASG12C and other mutations in lung cancers Clinical Trials. DOI: 10.1158/1538-7445.Am2020-709 |
0.305 |
|
2019 |
Christensen JG, Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, Sudhakar N, Bowcut V, Baer BR, Ballard JA, Burkard MR, Fell JB, Fischer JP, Vigers GP, ... ... Lito P, et al. The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients. Cancer Discovery. PMID 31658955 DOI: 10.1158/2159-8290.Cd-19-1167 |
0.441 |
|
2019 |
Wang VE, Xue JY, Frederick DT, Cao Y, Lin E, Wilson C, Urisman A, Carbone DP, Bernards R, Lito P, Settleman J, McCormick F, Flaherty KT. Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors Through Autocrine FGFR Pathway Activation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31515463 DOI: 10.1158/1078-0432.Ccr-18-2779 |
0.419 |
|
2019 |
Xue J, Zhao Y, Aronowitz J, Mai TT, Vides A, Qeriqi B, Kim D, Li C, Stanchina Ed, Mazutis L, Risso D, Lito P. Abstract LB-A04: Rapid non-uniform adaptation to conformation-specific KRAS G12C inhibition Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-Lb-A04 |
0.455 |
|
2019 |
Offin M, Pak T, Mondaca S, Montecalvo J, Rekhtman N, Halpenny D, Wu S, Kris M, Paik P, Riely G, Rudin C, Hyman D, Hellmann M, Drilon A, Land J, ... ... Lito P, et al. P1.04-39 Molecular Characteristics, Immunophenotype, and Immune Checkpoint Inhibitor Response in BRAF Non-V600 Mutant Lung Cancers Journal of Thoracic Oncology. 14: S455. DOI: 10.1016/J.Jtho.2019.08.942 |
0.355 |
|
2018 |
Mai TT, Lito P. A treatment strategy for KRAS-driven tumors. Nature Medicine. 24: 902-904. PMID 29988139 DOI: 10.1038/S41591-018-0111-X |
0.363 |
|
2018 |
Xue Y, Martelotto L, Baslan T, Vides A, Solomon M, Chadalavada K, DeStanchina E, Nanjangud G, Berger M, Lowe S, Reis-Filho JS, Rosen N, Lito P. Abstract B015: An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B015 |
0.402 |
|
2017 |
Arbour KC, Jordan EJ, Kim HR, Dienstag J, Yu H, Sanchez-Vega F, Lito P, Berger MF, Solit DB, Hellmann MD, Kris MG, Rudin CM, Ni A, Arcila ME, Ladanyi M, et al. Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29089357 DOI: 10.1158/1078-0432.Ccr-17-1841 |
0.373 |
|
2017 |
Xue Y, Martelotto L, Baslan T, Vides A, Solomon M, Mai TT, Chaudhary N, Riely GJ, Li BT, Scott K, Cechhi F, Stierner U, Chadalavada K, de Stanchina E, Schwartz S, ... ... Lito P, et al. An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer. Nature Medicine. PMID 28714990 DOI: 10.1038/Nm.4369 |
0.423 |
|
2016 |
Xue Y, Lito P. Predicting MEK inhibitor response in lung cancer: a proper signature is required. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27923842 DOI: 10.1158/1078-0432.Ccr-16-2576 |
0.373 |
|
2016 |
Naidoo J, Santos-Zabala ML, Iyriboz T, Woo KM, Sima CS, Fiore JJ, Kris MG, Riely GJ, Lito P, Iqbal A, Veach S, Smith-Marrone S, Sarkaria IS, Krug LM, Rudin CM, et al. Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. Clinical Lung Cancer. PMID 26898325 DOI: 10.1016/J.Cllc.2016.01.003 |
0.311 |
|
2016 |
Lito P, Solomon M, Li LS, Hansen R, Rosen N. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science (New York, N.Y.). 351: 604-8. PMID 26841430 DOI: 10.1126/Science.Aad6204 |
0.414 |
|
2016 |
Lito P, Solomon M, Hansen R, Li L, Rosen N. Abstract LB-071: Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-071 |
0.311 |
|
2014 |
Chung SS, Kim E, Park JH, Chung YR, Lito P, Teruya-Feldstein J, Hu W, Beguelin W, Monette S, Duy C, Rampal R, Telis L, Patel M, Kim MK, Huberman K, et al. Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Science Translational Medicine. 6: 238ra71. PMID 24871132 DOI: 10.1126/Scitranslmed.3008004 |
0.358 |
|
2014 |
Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadal S, Saborowski M, Kastenhuber E, Fellmann C, Ohara K, Morikami K, Miura T, Lukacs C, Ishii N, Lowe S, et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell. 25: 697-710. PMID 24746704 DOI: 10.1016/J.Ccr.2014.03.011 |
0.445 |
|
2014 |
Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Fellman C, Ohara K, Morikami K, Miura T, Lucas C, Ishii N, Lowe S, Rosen N. Abstract 4758: Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors Cancer Research. 74: 4758-4758. DOI: 10.1158/1538-7445.Am2014-4758 |
0.448 |
|
2014 |
Kim E, Chung SS, Park JH, Chung YR, Lito P, Feldstein J, Hu W, Beguilin W, Monette S, Duy C, Rampal R, Telis L, Patel M, Kim MK, Melnick AM, et al. Abstract 3140: Context specific effects of the BRAFV600E mutation on hematopoiesis identifies novel models of BRAF mutant hematopoietic disorders Cancer Research. 74: 3140-3140. DOI: 10.1158/1538-7445.Am2014-3140 |
0.386 |
|
2013 |
Lito P, Rosen N, Solit DB. Tumor adaptation and resistance to RAF inhibitors Nature Medicine. 19: 1401-1409. PMID 24202393 DOI: 10.1038/Nm.3392 |
0.391 |
|
2013 |
Chung SS, Park JH, Kim E, Chung YR, Hu W, Lito P, Feldstein JT, Rampal RK, Telis L, Patel M, Rosen N, Park CY, Tallman MS, Abdel-Wahab O. BRAFV600E Mutations Occur In The Hematopoietic Stem Cell Compartment In Hairy Cell Leukemia Blood. 122: 816-816. DOI: 10.1182/Blood.V122.21.816.816 |
0.331 |
|
2013 |
Lito P, Pratilas C, Joseph E, Tadi M, Halilovic E, Zubrowski M, Huang A, Stanchina Ed, Chandarlapaty S, Poulikakos P, Rosen N. Abstract 4630: Feedback dependent suppression of mitogenic signaling and its effect on RAF inhibition in BRAFV600E melanomas. Cancer Research. 73: 4630-4630. DOI: 10.1158/1538-7445.Am2013-4630 |
0.457 |
|
2012 |
Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, Huang A, Wong WL, Callahan MK, Merghoub T, Wolchok JD, de Stanchina E, Chandarlapaty S, Poulikakos PI, Fagin JA, et al. Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas Cancer Cell. 22: 668-682. PMID 23153539 DOI: 10.1016/J.Ccr.2012.10.009 |
0.432 |
|
2009 |
Lito P, Mets BD, Appledorn DM, Maher VM, McCormick JJ. Sprouty 2 regulates DNA damage-induced apoptosis in Ras-transformed human fibroblasts. The Journal of Biological Chemistry. 284: 848-54. PMID 19008219 DOI: 10.1074/Jbc.M808045200 |
0.57 |
|
2008 |
Lito P, Mets BD, Kleff S, O'Reilly S, Maher VM, McCormick JJ. Evidence that sprouty 2 is necessary for sarcoma formation by H-Ras oncogene-transformed human fibroblasts. The Journal of Biological Chemistry. 283: 2002-9. PMID 18048363 DOI: 10.1074/Jbc.M709046200 |
0.624 |
|
Show low-probability matches. |